Nintedanib in idiopathic and secondary pleuroparenchymal fibroelastosis.

Mouhamad Nasser Salim Aymeric Si-MohamedSégolène TurquierJulie TracletKaïs AhmadFrançois PhilitPhilippe BonniaudLara ChalabreysseFrançoise Thivolet-BéjuiVincent Cottin

Published in: Orphanet journal of rare diseases (2021)

In patients with PPFE, nintedanib treatment might be associated with slower decline in lung function, paving the way for prospective, controlled studies.

Keyphrases

lung function
idiopathic pulmonary fibrosis
cystic fibrosis
chronic obstructive pulmonary disease
air pollution
interstitial lung disease
rheumatoid arthritis
combination therapy